



### KEY FEATURES



#### High Growth Potential

CHB enables investors to access high growth potential through companies central to the development of biotechnology in China.



#### Targeted Exposure

CHB delivers targeted exposure to an emerging theme and industry.



#### ETF Efficiency

In a single trade, CHB delivers access to dozens of companies with high exposure to the biotech theme in China.

### FUND DETAILS

Inception Date	09/22/2020
Underlying Index	Solactive China Biotech Innovation Index
Number of Holdings	36
Assets Under Management	\$4.31 mil
Total Expense Ratio	0.67%
Distribution Frequency	Semi-Annually

### TRADING DETAILS

Ticker	CHB
CUSIP	37954Y251
Exchange	NASDAQ
Bloomberg IOPV Ticker	CHBIV
Index Ticker	SOLCHB

### PERFORMANCE (%)


	1M	YTD	1Y	Since Inception
NAV	2.05%	-2.27%	7.26%	4.83%
Market Price	2.63%	-2.38%	7.11%	4.88%
Index	2.11%	-1.72%	7.91	5.50%

### TOP 10 HOLDINGS (%) *Holdings Subject to Change*

Walvax Biotechnology Co-a	9.53%	Genscript Biotech Corp	5.47%
Changchun High-a	8.34%	Sino Biopharmaceutical	4.38%
Shenzhen Kangt-a	7.99%	Hualan Biologi-a	4.02%
Beigene Ltd-adr	7.48%	Fu Jian Anjoy-a	2.98%
Wuxi Biologics Cayman Inc	7.11%	Zai Lab Ltd-adr	2.92%

The performance data quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. High short-term performance of the Fund, when observed, is unusual and investors should not expect such performance to be repeated. Returns for periods greater than one year are annualized. [Click here](#) for standard performance as of the most recent quarter-end.

### INDUSTRY BREAKDOWN (%)



Biotechnology	57.17%
Pharmaceuticals	19.83%
Life Sciences Tools & Services	15.66%
Packaged Foods & Meats	2.98%
Distributors	2.34%
Health Care Equipment	1.33%
Health Care Distributors	0.69%

### RISK CHARACTERISTICS SINCE ETF INCEPTION

	Solactive China Biotech Innovation Index	MSCI ACWI Index
Annualized Volatility	27.91%	11.41%
Beta	0.64	1.00
Sharpe Ratio	0.20	2.31



## DEFINITIONS

Solactive China Biotech Innovation Index	The Solactive China Biotechnology Innovation Index is designed to provide exposure to exchange-listed companies that are directly involved in China's biotechnology industry. In constructing the index, the Solactive utilizes FactSet Industry classifications to identify companies that are directly involved in the biotechnology industry. Only those securities classified in the biotechnology industry according to FactSet as of each rebalance date are eligible for inclusion in the index. The index is weighted according to a modified capitalization weighting methodology and is reconstituted and re-weighted semi-annually.
MSCI ACWI Index	MSCI ACWI Index captures large and mid cap representation across 23 Developed Markets (DM) and 27 Emerging Markets (EM) countries. The index covers approximately 85% of the global investable equity opportunity set. DM countries include: Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Singapore, Spain, Sweden, Switzerland, the UK and the US. EM countries include: Argentina, Brazil, Chile, China, Colombia, Czech Republic, Egypt, Greece, Hungary, India, Indonesia, Korea, Kuwait, Malaysia, Mexico, Pakistan, Peru, Philippines, Poland, Qatar, Russia, Saudi Arabia, South Africa, Taiwan, Thailand, Turkey and United Arab Emirates.
Annualized Volatility	The annualized standard deviation of the daily returns of the security using the closing levels of the index during the 22 index-day period preceding that day.
Beta	Measures the volatility of the Fund price relative to the volatility in the market index and can also be defined as the percent change in the price of the Fund given a 1% change in the market index. A beta below one suggests that the Fund was less volatile than the market benchmark.
Sharpe Ratio	Measures the return for each unit of risk. The risk free rate is subtracted from the mean return and is divided by the standard deviation of returns.

Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Investments in securities in the Biotechnology and Health Care sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. Technology companies and companies that rely heavily on technology tend to be more volatile than the overall market, and are also heavily dependent on patent and intellectual property rights. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHB is non-diversified. The information provided is not intended for trading purposes, and should not be considered investment advice.

**Carefully consider the Fund's investment objectives, risk factors, charges, and expenses before investing. This and additional information can be found in the Fund's full or summary prospectus, which may be obtained by calling 1.888.493.8631, or by visiting [globalxetfs.com](http://globalxetfs.com). Please read the prospectus carefully before investing.**

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn't available, the midpoint between the national best bid and national best offer ("NBBO") as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund's shares typically do not trade in the secondary market until several days after the Fund's inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Global X Management Company LLC serves as an advisor to the Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO, 1 Freedom Valley Drive, Oaks, PA, 19456), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.